B. Schoser Et Al. , "COMET: Efficacy and safety of avalglucosidase alfa in late-onset Pompe disease participants after 97 weeks of treatment," EUROPEAN JOURNAL OF NEUROLOGY , vol.29, pp.59-60, 2022
Schoser, B. Et Al. 2022. COMET: Efficacy and safety of avalglucosidase alfa in late-onset Pompe disease participants after 97 weeks of treatment. EUROPEAN JOURNAL OF NEUROLOGY , vol.29 , 59-60.
Schoser, B., Kishnani, P., Diaz-Manera, J., Kushlaf, H., Ladha, S., Mozaffar, T., ... Straub, V.(2022). COMET: Efficacy and safety of avalglucosidase alfa in late-onset Pompe disease participants after 97 weeks of treatment. EUROPEAN JOURNAL OF NEUROLOGY , vol.29, 59-60.
Schoser, B. Et Al. "COMET: Efficacy and safety of avalglucosidase alfa in late-onset Pompe disease participants after 97 weeks of treatment," EUROPEAN JOURNAL OF NEUROLOGY , vol.29, 59-60, 2022
Schoser, B. Et Al. "COMET: Efficacy and safety of avalglucosidase alfa in late-onset Pompe disease participants after 97 weeks of treatment." EUROPEAN JOURNAL OF NEUROLOGY , vol.29, pp.59-60, 2022
Schoser, B. Et Al. (2022) . "COMET: Efficacy and safety of avalglucosidase alfa in late-onset Pompe disease participants after 97 weeks of treatment." EUROPEAN JOURNAL OF NEUROLOGY , vol.29, pp.59-60.
@article{article, author={B. Schoser Et Al. }, title={COMET: Efficacy and safety of avalglucosidase alfa in late-onset Pompe disease participants after 97 weeks of treatment}, journal={EUROPEAN JOURNAL OF NEUROLOGY}, year=2022, pages={59-60} }